Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC)

• Status: Completed
• Trial end date: 2017-03-01

Summary

Study Objective:

Primary

1. To evaluate the complete response (CR) rate with induction chemotherapy using Docetaxel, Cisplatin and Fluorouracil(TPF) followed by Docetaxel plus Cetuximab (TC) in concurrence with intensity-modulated radiotherapy (IMRT).

Secondary

1. To determine the overall response rate.

2. To determine the locoregional and distant control rate

3. To determine the progression-free survival (PFS)

4. To determine the overall survival (OS)

5. To determine the safety of the induction chemotherapy and concurrent chemoradiation plus Cetuximab.

• Phase: Phase 2

Details

• Lead Sponsor: Hong Kong Nasopharyngeal Cancer Study Group Limited
• Collaborators: Merck Sharp & Dohme Corp.; Roche Pharma AG; Sanofi; The University of Hong Kong
• Treatments: Cetuximab; Cisplatin; Docetaxel; Fluorouracil